Skip to main content
OpenTrials
Completed

NCT Number: NCT05130125

Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer

A multicenter, retrospective cohort observational study to evaluate the effectiveness and safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG)

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–39 year

Sex eligibility

Female

Study type

Observational

Primary location

CHA Fertility Hospital

Gyeonggi-do, South Korea

About this study

A multicenter, retrospective cohort observational study to evaluate the effectiveness and safety of fresh or frozen embryo transfer after ovarian hyperstimulation (administration of rFSH or HP-hMG alone or co-administration of rFSH and HP-hMG) to infertile female patients undergoing assisted reproductive technology to controlled ovarian hyperstimulation

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • First IVF-ET cycle patients

Exclusion criteria

Poor ovarian responder

  • At least two of the following three features must be present: (i) Advanced maternal age (≥ 40 years) or any other risk factor for Poor ovarian response (POR); (ii) A previous POR (≤ 3 oocytes with a conventional stimulation protocol); (iii) An abnormal ovarian reserve test (i.e. AFC < 5-7 follicles or AMH < 0.5-1.1 ng/mL)

Treatment and study plan

rFSH

Drug

rFSH or HP-hMG or rFSH and HP-hMG

Other names: HP-hMG, rFSH and HP-hMG

Primary outcomes

  1. Number of Oocytes

    Time frame: average of 14 days

    Counting number of Oocytes

Sponsors and collaborators

Lead sponsor

LG Chem

Industry

Registry information

Official study title

Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer After Ovarian Hyperstimulation (Administration of rFSH or HP-hMG Alone or Co-administration of rFSH and HP-hMG)

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Nov 22, 2021
Registry last updated
Aug 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.